Infectious Disease Book


Pyrimethamine sulfadoxine

Aka: Pyrimethamine sulfadoxine, Fansidar, Daraprim
  1. Indications: Malaria Prophylaxis and Treatment
    1. Areas with Chloroquine resistance
    2. Not recommended for routine prophylaxis
    3. Treatment in breakthrough Chloroquine Resistance
  2. Preparations
    1. Tablet: 25/500
  3. Directions
    1. Taking with food decreases gastric irritation
  4. Dosing: Prophylaxis
    1. Child
      1. Age 2-11 months: 1/8 tablet PO each week
      2. Age 1-3 years: 1/4 tablet PO each week
      3. Age 4-8 years: 1/2 tablet PO each week
      4. Age 9-14 years: 3/4 tablet PO each week
    2. Adolescent (over age 14 years): 1 tablet PO each week
    3. Adult: 25/500 mg tablet PO each week
  5. Dosing: Treatment
    1. Adult: 75/1500 mg for 1 dose
    2. Child: Double dose of prophylactic dose

Fansidar (C0060061)

Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH C001205
English Fansidar, fansidar
Derived from the NIH UMLS (Unified Medical Language System)

Daraprim (C0591326)

Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH D011739
English Daraprim, Glaxo Wellcome Brand of Pyrimethamine, GlaxoSmithKline Brand of Pyrimethamine, Wellcome Brand of Pyrimethamine
Derived from the NIH UMLS (Unified Medical Language System)

Pyrimethamine / Sulfadoxine (C0700599)

Definition (NCI) A combination product containing pyrimethamine and sulfadoxine. Pyrimethamine is a competitive inhibitor of dihydrofolate reductase (DHFR). DHFR is a key enzyme in the redox cycle for production of tetrahydrofolate, a cofactor that is required for the synthesis of DNA and proteins. Sulfadoxine competitively antagonizes paraaminobenzoic acid (PABA), resulting in disruption of folic acid synthesis and ultimately DNA synthesis. Sulfadoxine acts synergistically with pyrimethamine. (NCI04)
Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH C001205
SnomedCT 398770008, 53357005
English pyrimethamine-sulfadoxine, sulphadoxine-pyrimethamine, PYRIMETHAMINE/SULFADOXINE, Pyrimethamine + sulphadoxine, sulfadoxine + pyrimethamine, sulfadoxine + pyrimethamine (medication), Pyrimethamine + Sulphadoxine, Pyrimethamine + Sulfadoxine, Pyrimethamine / Sulfadoxine, fanasil, pyrimethamine drug combination, sulfadoxine-pyrimethamine, fanasil - pyrimethamine, Pyrimethamine with sulfadoxine, Pyrimethamine-sulphadoxine, Pyrimethamine-sulfadoxine, Pyrimethamine with sulphadoxine, Pyrimethamine with sulfadoxine (substance), Pyrimethamine + sulfadoxine (product), Pyrimethamine + sulfadoxine, pyrimethamine sulfadoxine, Pyrimethamine Sulfadoxine, Pyrimethamine-Sulfadoxine, Sulfadoxine and Pyrimethamine
Spanish pirimetamina-sulfadoxina, pirimetamina-sulfadoxina (sustancia), pirimetamina con sulfadoxina, pirimetamina + sulfadoxina (producto), pirimetamina + sulfadoxina
Derived from the NIH UMLS (Unified Medical Language System)

You are currently viewing the original '\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.

If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.

Please Contact Me as you run across problems with any of these versions on the website.

Navigation Tree